This clinical trial is focused on studying treatments for subfertility, a condition where individuals have difficulty conceiving. The study involves comparing two different methods of ovarian stimulation, which is a process used to encourage the ovaries to produce multiple eggs. The treatments being studied include Corifollitropin alfa (Elonva®) and a method called Progestin primed ovarian stimulation (PPOS). Additionally, the study will look at the use of Follitropin Beta (Puregon®) and Ganirelix (Orgalutran®) in conventional ovarian stimulation cycles.
The purpose of the study is to compare these treatments in terms of how they affect the quality of life and satisfaction of patients undergoing fertility preservation or preimplantation genetic testing (PGT). Participants will receive the treatments through subcutaneous injections, which means the medication is injected under the skin. The study will involve two cycles of treatment, and participants will be asked to complete questionnaires about their experiences and satisfaction after each cycle.
Throughout the study, participants will be monitored to assess their response to the treatments. The study aims to provide insights into which method may offer better outcomes for individuals seeking fertility treatments. The information gathered will help improve understanding of how these treatments impact patients’ lives and may guide future approaches to managing subfertility.
Belgium 
